119,279 Shares in Hims & Hers Health, Inc. $HIMS Purchased by Pathway Capital Management LP

Key Points

• Pathway Capital Management LP opened a new position of 119,279 shares (~$6.77M) in Hims & Hers during Q3, making HIMS 33.3% of Pathway’s holdings and the fund's largest position (about 0.05% of HIMS outstanding).
• Hims & Hers reported Q revenue of $598.98M, up 49.2% YoY, but missed EPS expectations ($0.06 vs. $0.09), leaving a net margin of 6.05% and a PE of 48.97; the consensus analyst rating is "Hold" with a target of $42.62.
• The board approved a $250M share repurchase program (up to ~3% of shares) even as insiders sold roughly 131,974 shares (~$4.76M) over the last quarter; insiders still own 13.71% of the company.

Pathway Capital Management LP bought a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 119,279 shares of the company's stock, valued at approximately $6,766,000. Hims & Hers Health accounts for 33.3% of Pathway Capital Management LP's holdings, making the stock its largest position. Pathway Capital Management LP owned 0.05% of Hims & Hers Health as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of HIMS. VIRGINIA RETIREMENT SYSTEMS ET Al raised its stake in shares of Hims & Hers Health by 0.8% during the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 25,600 shares of the company's stock valued at $1,452,000 after buying an additional 200 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Hims & Hers Health by 6.1% in the third quarter. GAMMA Investing LLC now owns 4,098 shares of the company's stock valued at $232,000 after purchasing an additional 236 shares during the period. Concurrent Investment Advisors LLC grew its holdings in shares of Hims & Hers Health by 1.8% during the 3rd quarter. Concurrent Investment Advisors LLC now owns 13,984 shares of the company's stock worth $793,000 after purchasing an additional 252 shares during the period. Bessemer Group Inc. increased its holdings in Hims & Hers Health by 105.8% in the 2nd quarter. Bessemer Group Inc. now owns 607 shares of the company's stock valued at $30,000 after purchasing an additional 312 shares during the last quarter. Finally, True Vision MN LLC increased its stake in Hims & Hers Health by 3.6% during the second quarter. True Vision MN LLC now owns 9,376 shares of the company's stock worth $467,000 after purchasing an additional 328 shares during the period. Institutional investors and hedge funds own 63.52% of the company's stock.

Hims & Hers Health Price Performance

Shares of NYSE:HIMS opened at $26.45 on Tuesday. The company has a debt-to-equity ratio of 1.67, a quick ratio of 1.64 and a current ratio of 1.88. The company has a market capitalization of $6.02 billion, a PE ratio of 48.97, a price-to-earnings-growth ratio of 4.46 and a beta of 2.37. Hims & Hers Health, Inc. has a one year low of $23.97 and a one year high of $72.98. The stock has a fifty day moving average of $34.11 and a 200-day moving average of $44.09.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its earnings results on Monday, November 3rd. The company reported $0.06 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.09 by ($0.03). The business had revenue of $598.98 million during the quarter, compared to analysts' expectations of $578.99 million. Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%. Hims & Hers Health's revenue for the quarter was up 49.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.32 EPS. As a group, equities analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hims & Hers Health declared that its board has approved a share repurchase program on Monday, November 17th that permits the company to repurchase $250.00 million in outstanding shares. This repurchase authorization permits the company to buy up to 3% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company's board believes its stock is undervalued.

Wall Street Analyst Weigh In

HIMS has been the subject of several recent analyst reports. Wall Street Zen cut Hims & Hers Health from a "hold" rating to a "sell" rating in a research note on Saturday, November 8th. Zacks Research downgraded shares of Hims & Hers Health from a "hold" rating to a "strong sell" rating in a research report on Monday, January 19th. Bank of America increased their price objective on Hims & Hers Health from $28.00 to $32.00 and gave the company an "underperform" rating in a research note on Tuesday, November 4th. Evercore ISI started coverage on shares of Hims & Hers Health in a report on Monday, January 12th. They issued an "in-line" rating and a $33.00 target price for the company. Finally, Barclays initiated coverage on shares of Hims & Hers Health in a report on Monday, December 8th. They set an "overweight" rating and a $48.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, nine have given a Hold rating and four have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $42.62.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, insider Deborah M. Autor sold 7,054 shares of the company's stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $258,952.34. Following the transaction, the insider owned 6,175 shares in the company, valued at approximately $226,684.25. This represents a 53.32% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Michael Chi sold 13,750 shares of Hims & Hers Health stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $504,762.50. Following the sale, the chief operating officer directly owned 305,161 shares of the company's stock, valued at $11,202,460.31. This trade represents a 4.31% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 131,974 shares of company stock worth $4,763,800. Company insiders own 13.71% of the company's stock.

Hims & Hers Health Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.

The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.

Want to see what other hedge funds are holding HIMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hims & Hers Health, Inc. (NYSE:HIMS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.